Literature DB >> 1387397

In vivo conversion of [3H]myoinositol to [3H]chiroinositol in rat tissues.

Y Pak1, L C Huang, K J Lilley, J Larner.   

Abstract

We report here the in vivo conversion of [3H]myoinositol to [3H]chiroinositol. After labeling intraperitoneally with [3H]myoinositol for 3 days to reach radioisotope equilibrium in urine, [3H]chiroinositol was isolated from tissues and purified after 6 N HCl hydrolysis by two sequential paper chromatographies and high performance liquid chromatography (HPLC). Percent conversion of [3H]myoinositol to [3H]chiroinositol was highest in urine (36%), liver (8.8%), muscle (8.8%), and blood (7.6%) with intestine, brain, kidney, spleen, and heart decreasing in percentage from 2.8 to 0.7%. Labeling of other inositol isomers including scyllo-, neo-, and epi-, and mucoinositol was minimal, approximately 0.06% of [3H]myoinositol. Glucose was unlabeled, but glucuronate, the product of myoinositol oxidation, was labeled up to 1.5% of the [3H] myoinositol. Acid hydrolysates of combined inositol-containing phospholipids contain significant labeled chiroinositol. [3H]Phosphatidylinositols and [3H]glycosylphosphatidylinositols were extracted from liver, muscle, and blood, isolated by thin layer chromatography, and inositols purified by HPLC after acid hydrolysis. Percent conversion of [3H]myoinositol to [3H] chiroinositol was highest in blood (60.4%) followed by muscle (7.7%) and liver (2.2%).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1387397

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

Review 1.  The "Other" Inositols and Their Phosphates: Synthesis, Biology, and Medicine (with Recent Advances in myo-Inositol Chemistry).

Authors:  Mark P Thomas; Stephen J Mills; Barry V L Potter
Journal:  Angew Chem Int Ed Engl       Date:  2015-12-22       Impact factor: 15.336

Review 2.  D-chiro-inositol glycans in insulin signaling and insulin resistance.

Authors:  Joseph Larner; David L Brautigan; Michael O Thorner
Journal:  Mol Med       Date:  2010-08-27       Impact factor: 6.354

3.  Determination of urinary Myo-/chiro-inositol ratios from Korean diabetes patients.

Authors:  Tae-Sik Jung; Jong-Ryeal Hahm; Jong-Jin Kim; Jung-Hwa Jung; Mi-Yeon Kang; Sung-Won Moon; Kang-Wan Lee; Ho-Cheol Kim; Jong-Deog Lee; Ji-Hye Kim; Deok-Ryong Kim; Soon-Il Chung
Journal:  Yonsei Med J       Date:  2005-08-31       Impact factor: 2.759

4.  chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects.

Authors:  I Asplin; G Galasko; J Larner
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

5.  Insulin stimulates the biosynthesis of chiro-inositol-containing phospholipids in a rat fibroblast line expressing the human insulin receptor.

Authors:  Y Pak; C R Paule; Y D Bao; L C Huang; J Larner
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

6.  Insulin-induced activation of glycerol-3-phosphate acyltransferase by a chiro-inositol-containing insulin mediator is defective in adipocytes of insulin-resistant, type II diabetic, Goto-Kakizaki rats.

Authors:  R V Farese; M L Standaert; K Yamada; L C Huang; C Zhang; D R Cooper; Z Wang; Y Yang; S Suzuki; T Toyota
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

7.  Human sodium/inositol cotransporter 2 (SMIT2) transports inositols but not glucose in L6 cells.

Authors:  Xiaobo Lin; Lina Ma; Robin L Fitzgerald; Richard E Ostlund
Journal:  Arch Biochem Biophys       Date:  2008-11-13       Impact factor: 4.013

8.  Relationships between urinary inositol excretions and whole-body glucose tolerance and skeletal muscle insulin receptor phosphorylation.

Authors:  April J Stull; John P Thyfault; Mark D Haub; Richard E Ostlund; Wayne W Campbell
Journal:  Metabolism       Date:  2008-11       Impact factor: 8.694

9.  Genetic modification of Bacillus subtilis for production of D-chiro-inositol, an investigational drug candidate for treatment of type 2 diabetes and polycystic ovary syndrome.

Authors:  Ken-ichi Yoshida; Masanori Yamaguchi; Tetsuro Morinaga; Maya Ikeuchi; Masaki Kinehara; Hitoshi Ashida
Journal:  Appl Environ Microbiol       Date:  2006-02       Impact factor: 4.792

10.  d- chiro-Inositol is absorbed but not synthesised in rodents.

Authors:  Xiaobo Lin; Lina Ma; Chaya Gopalan; Richard E Ostlund
Journal:  Br J Nutr       Date:  2009-07-09       Impact factor: 3.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.